Gilead Sciences
FDA Grants De Novo Authorization for Siemens Healthineers' Enhanced Liver Fibrosis Blood Test
The ELF Test provides prognostic information to assess the likelihood of a NASH patient progressing to cirrhosis and liver-related clinical events.
Siemens Healthineers, Gilead Sciences, Renown Institute Collaborate on Liver Fibrosis Testing
In a genetic population health study, the test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes, Renown Institute said.
HalioDx, Kite Pharma Extend Biomarker Collaboration
The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.
Biocartis, Kite Sign Development Agreement for Immunotherapy Assays
The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.
Siemens Healthineers Liver Fibrosis Test Gets FDA Breakthrough Device Designation
Used with other clinical evidence, Siemen Healthineer's blood-based test aids clinicians in assessing the fibrosis stage of chronic liver disease.